Abstract: A validated stability-indicating high-performance liquid chromatographic method has been developed for the simultaneous determination of Eprosartan and hydrochlorothiazide in tablet dosage forms. Chromatographic separation was performed on HPLC system of waters Model 2997 using X Bridge Shield RP18 (150 x 3.0 mm i.d., 3.5 µm particle size) column with a mixture of 0.1% formic acid and acetonitrile as mobile phase with a flow rate of 0.8 mL/min (gradient mode) with UV detection at 235 nm. The combinationof drugs was subjected to stress conditions such as acidic, alkaline, oxidation photolytic and thermal degradations and the method was validated as per ICH guidelines.
Introduction
Eprosartan 1 (EPR) is an angiotensin II receptor antagonist used for the treatment of high blood pressure ( Figure 1 ). It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. 
Figure 2. Chemical structures of hydrchlorothiazide (HCTZ)
Literature survey reveals that Eprosartan was determined by ultraviolet spectrophotometry 4 and high-performance liquid chromatography 5 in pharmaceutical preparations. Several analytical methods have been published for the determination of Hydrchlorothiazide in tablet susingflowinjection 6 , spectrophotometric [7] [8] [9] , densitometric 10 , HPLC [7] [8] [9] [10] [11] [12] [13] , electrophoretic [14] [15] andpolarographic 16 methods. The simultaneous determination of EPR and HCTZ was studied by HPTLC 17 , HPLC and derivative spectrophotmetry 18 . In the present study the authors have developed a simple, robust, precise and accurate RP-HPLC method has been developed for the simultaneous determination of hydrochlorothiazide and Eprosartan and validated as per ICH guidelines [19] [20] .
Instrumentation and chromatographic conditions
Liquid chromatographic separation was achieved by using a waters X Bridge shield RP-18 (150 mm × 3.0 mm, 3.5 µm) column and waters HPLC Model 2997 with Empower2 software and photodiode array detector, maintained at 45 ºC. Gradient mode elution was performed using Acetonitrile and 0.1% v/v formic acid. The overall run time was 20 min. and the flow rate of the mobile phase was 0.8 mL/min. The wavelength of the PDA detector was set at 235 nm. 5 µL of sample was injected into the HPLC system.
Experimental
Eprosartan standard (purity 99.4%) and was obtainedfrom Solvay, India) and hydrchlorothiazide standard (purity 99.8%) and was obtainedfrom Ranbaxy, India). Acetonitrile (HPLC grade), sodium hydroxide (Merck) and hydrochloric acid (Merck) and Hydrogen peroxide (Merck) and all other chemicals were of analytical grade.
The combination of Eprosartan and hydrochlorothiazide is available with brand names TEVENTEN HCT (Lupin) and TEVETEN PLUS (Torrent) (Label claim: 600 mg (EPR) and 12.5 mg (HCTZ).
Preparation of 0.1% formic acid solution
1.0 mL of Formic acid was added to a 1000 mL volumetric flask and made up to volume with HPLC grade water.
Preparation of stock solutions
Hydrochlorothiazide (2500 μg/mL) and Eprosartan (2400 μg/mL) stock solutions were prepared by accurately transferring 125 mg of HCTZ and 120 mg of EPR in a 50 mL volumetric flask with diluent. Standard solutions were prepared by further diluting 5 mL of the stock solution to 50 mL with diluent.
Working standard solutions were prepared on daily basis from the stock solutions by dilution with mobile phase and the solutions were filtered through 0.45 μm membrane filter prior to injection.
Method Validation

Linearity
A series of solutions were prepared from the stock solutions of Hydrochlorothiazide (1.0-300.0 µg/mL) and Eprosartan (19.2-750.3 µg/mL) using the diluents and 5 µL of each solution was injected in to the HPLC system and the peak area of the chromatogram was noted. A graph was drawn by taking the concentration of the drug solutions on the x-axis and the corresponding peak area on the y-axis.
Precision
The intra-day and inter-day precision of the assay method was evaluated by carrying out six independent assays of test samples of Eprosartan (540 μg/mL) and hydrochlorothiazide (250 μg/mL) against a qualified reference standard and the % RSD was calculated.
Accuracy
The accuracy of the assay method was evaluated in triplicate by spiking individual standard solutions at three concentration levels (80, 100 and 120%) and the percentage recoveries were calculated. Standard addition and recovery experiments were conducted to determine the accuracy of the method for the quantification of hydrochlorothiazide and Eprosartan respectively and the % RSD was calculated.
Robustness
The robustness of the assay method was established by introducing small deliberate changes in the HPLC conditions which included flow rate (0.72 and 0.88 mL/min), percentage of acetonitrile in the mobile phase (absolute ±2% composition) and column oven temperature (± 5 °C).
Limit of quantification (LOQ) and limit of detection (LOD)
The LOQ and LOD were determined as described in International Conference on Harmonization guidelines Q2 (R1).
Analysis of commercial formulations
Twenty tablets of two different brands containing Eprosartan and Hydrochlorothiazide were procured from the local medical store and analyzed as per the method and the percentage recovery was calculated from the linear regression equation using the mean peak area obtained from the respective chromatograms.
Forced degradation studies
Forced degradation studies 15 were intended to ensure the effective separation of Eprosartan and hydrochlorothiazide and their degradation peaks. Forced degradation studies were performed with the combined formulation containing 12000 μg/mL of Eprosartan and 250 μg/mL of Hydrochlorothiazide and diluted as per the requirement before injecting in to the system.
Acidic and alkaline degradation studies
Acid decomposition was carried out by refluxing the combined formulation of Eprosartan and of hydrochlorothiazide solution with 1 N HCl in a thermostat maintained at 80 ºC for 2 h and then the stressed sample was cooled, neutralized and diluted with mobile phase. Similarly alkaline degradation was conducted using 1 N NaOH for 2 h in thermostat maintained at 80 ºC. After cooling the solution was neutralized and diluted with mobile phase as per the requirement and 5 μL was injected in to the system.
Oxidation degradation studies
Solutions for oxidative stress studies were prepared by refluxing the combined formulation of Eprosartan and of hydrochlorothiazide solution with 1% H 2 O 2 and after refluxation for 2 h at 80 ºC in the thermostat the drug solution was cooled and diluted accordingly with the mobile phase.
Thermal degradation studies
For thermal stress testing, the combined formulation of Eprosartan and of hydrochlorothiazide was heated in an oven at 105 °C for 72 h, cooled and then injected in to the HPLC system.
Photolytic degradation studies
The combined formulation of Eprosartan and of hydrochlorothiazide was kept in photolytic chamber at 1289069 Lux Hours and 1024.2.66 Watt-Hour/m 2 and analyzed.
Humidity degradation
The combined formulation of Eprosartan and of Hydrochlorothiazide was kept in desiccator at 25 °C, 95% RH for 120 h. The sample solutions were prepared with the stressed sample with diluent as per the requirement and filtered through 0.45 µm filter. 5 µL of this solution was injected into the HPLC system and analysed.
Results and Discussion
A reversed-phase liquid chromatographic technique was developed to quantitate eprosartan and hydrochlorothiazide in pharmaceutical dosage forms (Tablets) and validated as per ICH guidelines. No stability indicating liquid chromatographic method has not yet been reported earlier.
Method development and optimization
For selection of column, a spiked sample of Eprosartan and hydrochlorothiazide was prepared and injected into HPLC system on different columns. The required system suitability criterion was obtained using X Bridge Shield RP-18 (150x3.0 mm), 3.5 µm column ( Table 1) . The optimized chromatographic conditions were shown in Table 2 and the chromatogram obtained for the blank was shown in Figure 3 . Table 1 . Selection of column in method optimization Column conditions Remark Luna C-18(2) (150x4.6 mm), 5 µm HCTZ peak eluting in the void. YMC pro pack C-18 (150x4.6 mm), 5 µm, 45 °C HCTZ peak eluting in the void.
Kromasil C-18 (150x 4.6 mm), 3.5 µm Flow rate 1.1 mL/min, Gradient2 HCTZ peak eluting in the void. Eprosartan peak co-eluting with the blank peak. X Bridge RP-18 (150x4.6 mm) 3.5 µm Eprosartan peak co-eluting with the blank peak X Bridge Shield RP-18 (150x3.0 mm), 3.5 µm Eprosartan peak separated from blank peak X Bridge Shield RP-18 (150x3.0 mm), 3.5 µm, different gradient Eprosartan peak separated from blank peak
Method validation
The typical chromatogram of hydrochlorothiazide and Eprosartan was shown in Figure 4 and the corresponding peak purity plots were shown in Figure 5 . Beer-Lambert's law was obeyed over the concentration range 1-300 μg/mL for hydrochlorothiazide and 19.2-750.3 μg/mL for Eprosartan respectively (Table 3) The LOQ and LOD for Eprosartan were found to be 2.305 μg/mL and 0.761 μg/mL respectively whereas the LOQ and LOD for Hydrochlorothiazide were found to be 0.921 μg/mL and 0.304 μg/mL respectively. The % RSD for intra-day and inter-day precision study was found to be 0.14-0.36 and 0.18-0.33 for EPR (Table 5) where as the RSD for intra-day and inter-day precision study for HCTZ was found to be 0.16-0.34 and 0.15-0.34 (Table 4) respectively which is less than 2 % indicating that the method is precise. Chem Sci Trans., 2014, 3(2), 544-555
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The % RSD accuracy study was found to be 0.25-1.43 for EPR and 0.27-0.36 for HCTZ (Table 6) respectively. The % RSD for robustness study was found to be 0.13-0.78 for EPR and 0.15-0.54 for HCTZ (Table 7) respectively. 
Analysis of commercial formulations
The proposed method was applied for the determination of Hydrochlorothiazide and Eprosartan tablets and the percentage recovery was found to be 99.40-99.44 and 99.23-99.44 respectively (Table 8 ) and no interference was observed with the excipients. 
Forced degradation studies/specificity
During acidic degradation, the chromatogram shows peaks at 2.854 min and 7.281 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively ( Figure 6 ). On acidic degradation HCTZ has not at all undergone degradation where as 1.04% of decomposition was observed with EPR. The purity angle (0.083) was less than the purity threshold (1.030) indicating that EPR does not interference with degradants and similarly the purity angle (0.349) was less than the purity threshold (1.051) for HCTZ. Therefore it can be concluded that the method is specific and selective. During alkaline degradation, the chromatogram shows peaks at 2.858 min and 7.284 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively. 1.17 % of EPR has undergone alkaline degradation and only 0.66 % of HCTZ was decomposed (Figure 7) . The purity angle (0.079) for EPR was less than the purity threshold (1.030) indicating that no interference of degradants and similarly the purity angle (0.0678) was less than the purity threshold (2.125) for HCTZ.
During oxidative degradation, the chromatogram shows peaks at 2.856 min and 7.290 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively. During oxidative degradation about 3.60 % of EPR and 3.52 % of HCTZ have undergone decomposition without degradants (Figure 8 ). The purity angle (0.080) was less than the purity threshold (1.030) indicating that EPR peak was well separated and similarly the purity angle (0.762) was less than the purity threshold (2.023) for HCTZ.
During thermal degradation the chromatogram shows peaks at 2.867 min and 7.326 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively. HCTZ has undergone 1.22 % degradation where as 2.65 % of decomposition was observed with EPR ( Figure 9 ). The purity angle (0.107) was less than the purity threshold (1.079) indicating that EPR indicating that there is no interference. Similarly the purity angle (0.045) was less than the purity threshold (1.060) for HCTZ.
During photolytic degradation the chromatogram shows peaks at 2.868 min and 7.332 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively ( Figure 10 ). HCTZ has not at all undergone degradation where as 2.01% of decomposition was observed with EPR. The purity angle (0.110) was less than the purity threshold (1.082) indicating that EPR indicating that there is no interference and similarly the purity angle (0.048) was less than the purity threshold (1.061) for HCTZ. Therefore it can be concluded that the method is specific and selective. As no new degradants were observed mass spectral analysis was not performed. On humidity degradation the chromatogram shows peaks at 2.864 min and 7.326 min indicating the elution of Hydrochlorothiazide and Eprosartan respectively (Figure 11 ). On humidity exposure to 95%RH at 25°C for 120 hours, HCTZ has not at all undergone degradation where as 1.27 % of decomposition was observed with EPR . The purity angle (0.107) was less than the purity threshold (1.070) indicating that EPR indicating that there is no interference and similarly the purity angle (0.048) was less than the purity threshold (1.063) for HCTZ. Therefore it can be concluded that the method is specific and selective.
H C T Z -2 . Figure 11 . Typical chromatogram of Hydrochlorothiazide (5 μg/mL) and Eprosartan (240 μg/mL) (Humidity degradation) The system suitability tests were performed to ensure that the complete testing system was suitable for the intended application. The tailing factor was 1.11 (HCTZ) and 1.04 (EPR) which is <1.5-2 or <2 and the theoretical plates were found to be 3082 (HCTZ) and 97156 (EPR) which is >2000. A brief summary of forced degradation studies of Eprosartan and Hydrochlorothiazide was given in Table 9 . 
Conclusion
The present developed RP-HPLC method was stability indicating simple, specific, precise, accurate and robust. It can be applied for the determination of Eprosartan and Hydrochlorothiazide in pharmaceutical dosage forms as well as for pharmacokinetic studies. 
